Circulating tumor DNA in the blood of patients treated for non-Hodgkin lymphoma can be used to identify those who are relapsing earlier, and with greater accuracy, than conventional monitoring, according to a study by researchers at the School of Medicine. The finding is important because it will allow clinicians to quickly identify patients who need additional treatment.
http://ift.tt/1DD08Je
No comments:
Post a Comment